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DDiscussion
Dr Christopher A. Caldarone (Toronto, Ontario, Canada).
Any innovation typically goes through 3 phases: a boom phase,
a bit of a disillusionment phase, and then back to a niche phase.
The hybrid procedure is no exception.
In the boom phase, it seems like the greatest innovation in the
world and widely applicable. Then, a disillusionment phase occurs
as the limitations of the innovation became apparent. Finally, it
generally finds its place in the niche phase.
At the Hospital for Sick Children, we right now have 4
indications for using the hybrid procedure: (1) as an alternative
to the Norwood; (2) pretransplant palliation in patients already
listed for transplantation; (3) to delay single ventricle, 2-ventricle
decision-making; and (4) as the ‘‘salvage procedure’’ in the group
of patients unfit for a Norwood procedure. That is the group you
have tackled, and you have tackled it well.
In our version of the salvage procedure, however, we typically
will control the patient’s pulmonary blood flow with the bands and
place a ductal stent. If the patient survives, the patient will
subsequently undergo a comprehensive stage 2 procedure. In
your paradigm, you have interposed a Norwood procedure
between attaining stability and your second stage procedure.
So I guess the most obvious question is: if you have achieved a
period of stability, you have succeeded in neutralizing these
preoperative comorbidities. Why not just stent the duct and allow
the patient to return for a comprehensive stage 2 rather than
interposing a new hazard phase associated with a Norwood
procedure, which would necessarily include all the potential
hemodynamic instability that accompanies having a balanced
circulation after a large operation?
Dr Gomide. Thank you for your comments. We think that the
hybrid procedure, as mentioned, and has been shown by some of
your studies, might not offer appropriate oxygen delivery and
that the Norwood procedure would offer better physiologic
conditions for patients in terms of antegrade flow and oxygen
delivery.
We also fear that a metal stent might provoke coarctation at the
point of the ductus arteriosus and interfere in the backflow to the
aorta. Thus, we decided to avoid the stent. This is the basic itemThe Journal of Thoracic and Carwe wanted to avoid. Also, because the patient was in a better
condition, we wanted to offer the NW1 procedure because of
these factors. Finally, because we have had satisfactory results
with the NW1, we thought that patients in better condition would
have a better prognosis with the NW1 than they would have with a
stent.
Dr Caldarone. Well, fair enough. I think the hemodynamic
studies you refer to really showed that alteration of hemodynamics
is mostly due to afterloading, acutely afterloading the neonatal
ventricle. Once you are beyond a few days, you have probably
passed that hazard phase. Anyway, it is worth ongoing discussion
about which strategy might be superior.
The other point I noticed in your report was that the preopera-
tive morbidities were grouped together, and you basically counted
them in a scoring system to identify the patients appropriate for the
salvage-type procedure. I like that method, but it does suggest that
each 1 of these preoperative comorbidities would have an
equivalent effect. I was wondering if, in your analysis, did you
try to analyze which of the preoperative comorbidities were
most important in terms of predicting a poor outcome?
Dr Gomide. No. This is one point we wanted to address.
Actually, we could have used a comprehensive score, but this study
is not about scoring the patients. We just wanted to keep it simple
and to address the number of comorbidities that are easily checked
in each patient and show that the patient at high risk can be moved
to a lower risk. We did not address the importance of each different
risk in terms of the importance for the outcome. Actually, we just
wanted to keep it simple and to send the following message: if we
have a patient with a high risk, and we reduce this patient’s risk, the
patient can have the same outcome as a patient with a conventional
risk for the Norwood.
Dr Caldarone. Going forward, will you use some more clearly
defined paradigm? In other words, if a patient shows up and starts
to accumulate preoperative comorbidities and if they hit number 4,
will you then go to the salvage strategy or will you refine that
trigger for going to the salvage strategy in the future?
Dr Gomide. No, this is a retrospective study. Actually, we
observed that those patients had this high number of comorbidities.
Usually in our practice, what happens is that the patient arrives and
is assessed clinically. If the patient is in a condition to undergo the
Norwood procedure, the patient will receive the Norwood. As we
mentioned, the indication for the Norwood depends on the clinical
status of the patient, not by counting the number of risk factors.
Actually, it is a clinical assessment. Once the patient is stable
enough, the patient will undergo the Norwood. It is not a matter
of how many preoperative comorbidities are present. This was
checked retrospectively, and it was just a cutpoint that was set.
Dr Caldarone. I guess what I am asking is: Will the results of
this study guide your decision-making in the future?
Dr Gomide. Well, they certainly will, but not in these terms. I
think that the most important message of this study is that those
patients with high risk, independently of the number of risk
factors, can have the risk category lowered by offering bPAB,
and this is the main message. It is not necessary to count the
number of risk factors and then decide whether we are going to
perform a Norwood or bPAB.
Dr Christian Pizarro (Wilmington, Del). That was an
interesting study and a very timely communication, particularlydiovascular Surgery c Volume 146, Number 5 1151
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Dbased on the discussion we had on Sunday. It seems we are finally
reaching a point where we could learn and distill who are the best
patients to undergo the hybrid procedure and who are the ones to
undergo the Norwood.
Almost about 10 years ago by now, our group and the group in
Michigan communicated the effectiveness of pulmonary artery
banding to do exactly what you describe. Also, I think that because
we embraced that approach more broadly, we went on to treat
patients with nonmodifiable factors such as chromosomal
anomalies. Not surprisingly, when we communicated those results,
5 years ago at the meeting of the European Association for
Cardio-Thoracic Surgery, the outcome, when you looked beyond
the second stage, was no different, and it was close to 50% to
60% mortality.
I think that although you have shown that there was no
difference at 1 year, you do not have the power to make that
statement. Also, I think it is likely there will be a difference. So,
you have 80% survival compared with about 62%. Experience
has told us that, for example, there are certain conditions that
you might think you would be able to modify, such as renal
dysfunction. For instance, a patient presents in shock with
significant renal dysfunction, liver dysfunction, and whatnot,
sometimes you are able to help that patient recover normal
function, not just to make urine and lower their creatinine but to
completely resolve their dysfunction. However, some of those
patients will not.
So, some of the difference that you observe in the high-risk
group is probably related to, for example, ventilator-associated
lung disease, residual renal dysfunction, and so forth. Did you
have an opportunity to actually study that patient population, the
ones who were in the high-risk group and had lower survival at
1 year to determine how many of those factors that were perceived
as recoverable actually had a sequela and how that affected the
mortality?
Dr Gomide. Yes. We have had 5 deaths in the bPAB group.
Three patients died of sepsis and severe multiorgan failure, one
of a complex congenital hepatic malformation, and one died after
a Rashkind procedure, unexplainably. Thus, the 3 patients who
died of sepsis and the patient who died of congenital hepatic
dysfunction are patients that perhaps we could not offer1152 The Journal of Thoracic and Cardiovascular Surimprovement by banding the pulmonary arteries, because the
adjustment of the Qp/Qs might improve the end-organ perfusion
but might not offer an improvement to the inflammatory response
caused by sepsis. Thus, perhaps the septic patient will not have the
same improvement as the nonseptic patient, or, even some septic
patients who respond more aggressively to the infection might
not respond to the bPAB, while some others would respond. To
identify those patients, we will additional studies.
In the case of the primary end-organ failure, perhaps we do not
improve it because it is the primary failure of the organ, and
improving the perfusion might not correlate with better outcomes.
Dr Pizarro. As you accumulate more experience, I would
encourage you to actually study and determine how many of those
patients with a recoverable lesion actually had a sequela and what
the role of that was later in their life.
Dr Shunji Sano (Okayama, Japan). We have also adopted the
rapid 2-stage banding for high-risk patients, as we presented
previously. In our series, the rapid 2-stage operation occupies
almost 20% to 30% of our series. Our indication for the rapid
2-stage is slightly different from yours. Most of our indications
have been the patient with HLHS and an intact atrial septum or
restrictive atrial septal defect with high pulmonary vascular
resistance. I am sure you have similar patients in your series, but
your indication was different. What is your strategy for the patient
with an intact atrial septum or restrictive atrial septal defect or
associated with total anomalous pulmonary venous drainage. Do
you do a rapid 2-stage in these patients or just the ordinary
Norwood?
DrGomide.Well, these patients with the restrictive atrial septal
defect usually undergo the Norwood. Our strategy differs from
yours in that we are not analyzing the usual anatomically related
risk factors but the modifiable risk factors. Therefore, the patients
had the same anatomic risk factors as the usual patients. We
actually excluded the patients with restrictive atrial septal defect
from this study. However, all the other commonly known risk
factors, such as aortic atresia or total anomalous pulmonary venous
drainage, were not considered risk factors in our group, because
our results did not show different outcomes for these patients.
Thus, they were treated in terms of the clinical risk factors that
were related.gery c November 2013
